Selected research
Industry Research
GABAB Receptor Agonists Industry Research Report 2026
Market perspective
The global GABAB Receptor Agonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for GABAB Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for GABAB Receptor Agonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for GABAB Receptor Agonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of GABAB Receptor Agonists include Xi'an Libang Pharmaceuticals, Xi'an Hanfeng Pharmaceuticals, Sun Pharma, Hemony Pharmaceutical, Sichuan Ren'an Pharmaceuticals, Novartis, Nanjing Haina Pharmaceutical, China Resources Double Crane Pharmaceuticals and Fuan Pharmaceutical Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global GABAB Receptor Agonists market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
GABAB Receptor Agonists Market by Company
Xi'an Libang Pharmaceuticals
Xi'an Hanfeng Pharmaceuticals
Sun Pharma
Hemony Pharmaceutical
Sichuan Ren'an Pharmaceuticals
Novartis
Nanjing Haina Pharmaceutical
China Resources Double Crane Pharmaceuticals
Fuan Pharmaceutical Group
Chengdu Beite
Viatris
Jazz Pharmaceuicals
Hikma
GABAB Receptor Agonists Segment by Type
Baclofen
γ-hydroxybutyrate(GHB)）
GABAB Receptor Agonists Segment by Application
Hospital
Clinic
Other
GABAB Receptor Agonists Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABAB Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GABAB Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABAB Receptor Agonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of GABAB Receptor Agonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of GABAB Receptor Agonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of GABAB Receptor Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Baclofen
- γ-hydroxybutyrate(GHB)）
Applications
- Hospital
- Clinic
- Other
Companies covered
- Xi'an Libang Pharmaceuticals
- Xi'an Hanfeng Pharmaceuticals
- Sun Pharma
- Hemony Pharmaceutical
- Sichuan Ren'an Pharmaceuticals
- Novartis
- Nanjing Haina Pharmaceutical
- China Resources Double Crane Pharmaceuticals
- Fuan Pharmaceutical Group
- Chengdu Beite
- Viatris
- Jazz Pharmaceuicals
- Hikma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global GABAB Receptor Agonists Market Size (2021-2032)
- 2.2.2 Global GABAB Receptor Agonists Sales (2021-2032)
- 2.2.3 Global GABAB Receptor Agonists Market Average Price (2021-2032)
- 2.3 GABAB Receptor Agonists by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Baclofen
- 2.3.3 γ-hydroxybutyrate(GHB)）
- 2.4 GABAB Receptor Agonists by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global GABAB Receptor Agonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global GABAB Receptor Agonists Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global GABAB Receptor Agonists Revenue of Manufacturers (2021-2026)
- 3.4 Global GABAB Receptor Agonists Average Price by Manufacturers (2021-2026)
- 3.5 Global GABAB Receptor Agonists Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of GABAB Receptor Agonists, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of GABAB Receptor Agonists, Product Type & Application
- 3.8 Global Manufacturers of GABAB Receptor Agonists, Established Date
- 3.9 Global GABAB Receptor Agonists Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Xi'an Libang Pharmaceuticals
- 4.1.1 Xi'an Libang Pharmaceuticals Company Information
- 4.1.2 Xi'an Libang Pharmaceuticals Business Overview
- 4.1.3 Xi'an Libang Pharmaceuticals GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Xi'an Libang Pharmaceuticals GABAB Receptor Agonists Product Portfolio
- 4.1.5 Xi'an Libang Pharmaceuticals Recent Developments
- 4.2 Xi'an Hanfeng Pharmaceuticals
- 4.2.1 Xi'an Hanfeng Pharmaceuticals Company Information
- 4.2.2 Xi'an Hanfeng Pharmaceuticals Business Overview
- 4.2.3 Xi'an Hanfeng Pharmaceuticals GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Xi'an Hanfeng Pharmaceuticals GABAB Receptor Agonists Product Portfolio
- 4.2.5 Xi'an Hanfeng Pharmaceuticals Recent Developments
- 4.3 Sun Pharma
- 4.3.1 Sun Pharma Company Information
- 4.3.2 Sun Pharma Business Overview
- 4.3.3 Sun Pharma GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sun Pharma GABAB Receptor Agonists Product Portfolio
- 4.3.5 Sun Pharma Recent Developments
- 4.4 Hemony Pharmaceutical
- 4.4.1 Hemony Pharmaceutical Company Information
- 4.4.2 Hemony Pharmaceutical Business Overview
- 4.4.3 Hemony Pharmaceutical GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hemony Pharmaceutical GABAB Receptor Agonists Product Portfolio
- 4.4.5 Hemony Pharmaceutical Recent Developments
- 4.5 Sichuan Ren'an Pharmaceuticals
- 4.5.1 Sichuan Ren'an Pharmaceuticals Company Information
- 4.5.2 Sichuan Ren'an Pharmaceuticals Business Overview
- 4.5.3 Sichuan Ren'an Pharmaceuticals GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sichuan Ren'an Pharmaceuticals GABAB Receptor Agonists Product Portfolio
- 4.5.5 Sichuan Ren'an Pharmaceuticals Recent Developments
- 4.6 Novartis
- 4.6.1 Novartis Company Information
- 4.6.2 Novartis Business Overview
- 4.6.3 Novartis GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis GABAB Receptor Agonists Product Portfolio
- 4.6.5 Novartis Recent Developments
- 4.7 Nanjing Haina Pharmaceutical
- 4.7.1 Nanjing Haina Pharmaceutical Company Information
- 4.7.2 Nanjing Haina Pharmaceutical Business Overview
- 4.7.3 Nanjing Haina Pharmaceutical GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Nanjing Haina Pharmaceutical GABAB Receptor Agonists Product Portfolio
- 4.7.5 Nanjing Haina Pharmaceutical Recent Developments
- 4.8 China Resources Double Crane Pharmaceuticals
- 4.8.1 China Resources Double Crane Pharmaceuticals Company Information
- 4.8.2 China Resources Double Crane Pharmaceuticals Business Overview
- 4.8.3 China Resources Double Crane Pharmaceuticals GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 China Resources Double Crane Pharmaceuticals GABAB Receptor Agonists Product Portfolio
- 4.8.5 China Resources Double Crane Pharmaceuticals Recent Developments
- 4.9 Fuan Pharmaceutical Group
- 4.9.1 Fuan Pharmaceutical Group Company Information
- 4.9.2 Fuan Pharmaceutical Group Business Overview
- 4.9.3 Fuan Pharmaceutical Group GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Fuan Pharmaceutical Group GABAB Receptor Agonists Product Portfolio
- 4.9.5 Fuan Pharmaceutical Group Recent Developments
- 4.10 Chengdu Beite
- 4.10.1 Chengdu Beite Company Information
- 4.10.2 Chengdu Beite Business Overview
- 4.10.3 Chengdu Beite GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Chengdu Beite GABAB Receptor Agonists Product Portfolio
- 4.10.5 Chengdu Beite Recent Developments
- 4.11 Viatris
- 4.11.1 Viatris Company Information
- 4.11.2 Viatris Business Overview
- 4.11.3 Viatris GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Viatris GABAB Receptor Agonists Product Portfolio
- 4.11.5 Viatris Recent Developments
- 4.12 Jazz Pharmaceuicals
- 4.12.1 Jazz Pharmaceuicals Company Information
- 4.12.2 Jazz Pharmaceuicals Business Overview
- 4.12.3 Jazz Pharmaceuicals GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Jazz Pharmaceuicals GABAB Receptor Agonists Product Portfolio
- 4.12.5 Jazz Pharmaceuicals Recent Developments
- 4.13 Hikma
- 4.13.1 Hikma Company Information
- 4.13.2 Hikma Business Overview
- 4.13.3 Hikma GABAB Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Hikma GABAB Receptor Agonists Product Portfolio
- 4.13.5 Hikma Recent Developments
5 Global GABAB Receptor Agonists Market Scenario by Region
- 5.1 Global GABAB Receptor Agonists Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global GABAB Receptor Agonists Sales by Region: 2021-2032
- 5.2.1 Global GABAB Receptor Agonists Sales by Region: 2021-2026
- 5.2.2 Global GABAB Receptor Agonists Sales by Region: 2027-2032
- 5.3 Global GABAB Receptor Agonists Revenue by Region: 2021-2032
- 5.3.1 Global GABAB Receptor Agonists Revenue by Region: 2021-2026
- 5.3.2 Global GABAB Receptor Agonists Revenue by Region: 2027-2032
- 5.4 North America GABAB Receptor Agonists Market Facts & Figures by Country
- 5.4.1 North America GABAB Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America GABAB Receptor Agonists Sales by Country (2021-2032)
- 5.4.3 North America GABAB Receptor Agonists Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe GABAB Receptor Agonists Market Facts & Figures by Country
- 5.5.1 Europe GABAB Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe GABAB Receptor Agonists Sales by Country (2021-2032)
- 5.5.3 Europe GABAB Receptor Agonists Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific GABAB Receptor Agonists Market Facts & Figures by Country
- 5.6.1 Asia Pacific GABAB Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific GABAB Receptor Agonists Sales by Country (2021-2032)
- 5.6.3 Asia Pacific GABAB Receptor Agonists Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America GABAB Receptor Agonists Market Facts & Figures by Country
- 5.7.1 South America GABAB Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America GABAB Receptor Agonists Sales by Country (2021-2032)
- 5.7.3 South America GABAB Receptor Agonists Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa GABAB Receptor Agonists Market Facts & Figures by Country
- 5.8.1 Middle East and Africa GABAB Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa GABAB Receptor Agonists Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa GABAB Receptor Agonists Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global GABAB Receptor Agonists Sales by Type (2021-2032)
- 6.1.1 Global GABAB Receptor Agonists Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global GABAB Receptor Agonists Sales Market Share by Type (2021-2032)
- 6.2 Global GABAB Receptor Agonists Revenue by Type (2021-2032)
- 6.2.1 Global GABAB Receptor Agonists Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global GABAB Receptor Agonists Revenue Market Share by Type (2021-2032)
- 6.3 Global GABAB Receptor Agonists Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global GABAB Receptor Agonists Sales by Application (2021-2032)
- 7.1.1 Global GABAB Receptor Agonists Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global GABAB Receptor Agonists Sales Market Share by Application (2021-2032)
- 7.2 Global GABAB Receptor Agonists Revenue by Application (2021-2032)
- 7.2.1 Global GABAB Receptor Agonists Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global GABAB Receptor Agonists Revenue Market Share by Application (2021-2032)
- 7.3 Global GABAB Receptor Agonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 GABAB Receptor Agonists Value Chain Analysis
- 8.1.1 GABAB Receptor Agonists Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 GABAB Receptor Agonists Production Mode & Process
- 8.2 GABAB Receptor Agonists Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 GABAB Receptor Agonists Distributors
- 8.2.3 GABAB Receptor Agonists Customers
9 Global GABAB Receptor Agonists Analyzing Market Dynamics
- 9.1 GABAB Receptor Agonists Industry Trends
- 9.2 GABAB Receptor Agonists Industry Drivers
- 9.3 GABAB Receptor Agonists Industry Opportunities and Challenges
- 9.4 GABAB Receptor Agonists Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst